Gainers

• Bio Green Med Solution (NASDAQ:BGMS) shares rose 152.8% to $2.68 during Thursday's after-market session. The market value of their outstanding shares is at $5.8 million.
• Basel Medical Group (NASDAQ:BMGL) shares rose 18.55% to $0.57. The market value of their outstanding shares is at $12.3 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) stock rose 12.24% to $0.55. The market value of their outstanding shares is at $3.0 million.
• NuCana (NASDAQ:NCNA) stock rose 11.24% to $2.24. The company's market cap stands at $8.4 million.
• ALPS Group (NASDAQ:ALPS) stock moved upwards by 8.23% to $0.76. The company's market cap stands at $118.1 million.
• Codexis (NASDAQ:CDXS) shares increased by 6.07% to $2.97. The market value of their outstanding shares is at $247.2 million.

Losers

• Indaptus Therapeutics (NASDAQ:INDP) stock declined by 29.7% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $250.2 million.
• Nyxoah (NASDAQ:NYXH) stock fell 22.57% to $2.23. The market value of their outstanding shares is at $128.2 million.
• BioRestorative Therapies (NASDAQ:BRTX) stock declined by 10.67% to $0.37. The market value of their outstanding shares is at $8.6 million.
• Picard Medical (AMEX:PMI) stock decreased by 10.15% to $0.29. The market value of their outstanding shares is at $28.7 million.
• Exicure (NASDAQ:XCUR) shares fell 7.72% to $2.75. The company's market cap stands at $20.1 million. The company's, Q1 earnings came out 4 days ago.
• Nexalin Technology (NASDAQ:NXL) shares declined by 7.38% to $0.5. The market value of their outstanding shares is at $11.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.